Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of bendamustine + rituximab with or without acalabrutinib in previously untreated mantle cell lymphoma
CTR20192587Phase 3Active
- Sponsor
- AstraZeneca
- Start
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of acalabrutinib in mantle cell lymphoma (MCL), sponsored by AstraZeneca. Started Oct 2020; status: active.
02
Drugs
acalabrutinib
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on CTR20192587.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20192587.